drugset / Trial / NCT00478335

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

NCT00478335 ↗

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).

Timeline

Start
2007-05
Primary completion
2012-10
Completion
2012-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitonin Protein / enzyme biologic — Intranasal
Subject Sildenafil Unknown 25 mg —
Subject Sildenafil Unknown 50 mg —
Background Amiloride Small molecule 2.5 mg —
Background Amiloride Small molecule 5 mg —
Background Hydrochlorothiazide Unknown 25 mg —
Background Hydrochlorothiazide Unknown 50 mg —
Background Indomethacin Small molecule 50 mg —